# US 10,821,151 B2 · Compositions and methods for treating cancer and persistent viral infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,821,151 B2
- Document ID: US10821151B2
- Status: Granted
- Kind: B2
- Application number: 16/512,329
- Filed: 2019-07-15
- Published: 2019-10-31
- Granted: 2020-11-03
- Earliest claimed: 2015-04-27
- Assignees: Susavion Biosciences, Inc.
- Applicants: Susavion Biosciences, Inc.
- Inventors: Laura L. Eggink; J. Kenneth Hoober
- Web page: https://patentgrep.com/patent/US10821151B2

## CPC

- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/05: {Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer}
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2039/572: {cytotoxic response}
- A61K 2039/575: {humoral response}
- C12N 2740/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16088: for redistribution
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The methods and compounds disclosed herein are useful in treating a subject having cancer or a viral infection by modulating the innate and adaptive immune systems typically by both inhibiting the function of inhibitory receptors and enhancing activity of activating receptors. Preferred therapeutic compositions comprise a carrier; at least one agent selected from the group consisting of: an anti-inflammatory agent, a cytotoxic T cell proliferation agent, or a NK cell proliferation agent; and a therapeutic peptide of the invention. In certain embodiments the compositions further include a second therapeutic peptide and/or an immunoglobulin admixed therewith in an amount sufficient to enhance passive immunoprotection in the subject.

## Claims

### Claim 1

A method of activating a lectin-type receptor specific for N-actetylgalactosamine or galactose in a cell, the method comprising:
treating the cell with a therapeutic peptide or a multivalent structured polypeptide comprising multiple copies of the therapeutic peptide;
wherein the therapeutic peptide consists of 6 to 8 amino acids comprising NQHTPR (SEQ ID NO:5), and the therapeutic peptide or multivalent structured polypeptide is in an amount sufficient to activate the lectin-type receptor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the lectin-type receptor is CLEC10a, langerin, ASGPR-1 or dectin-1.

### Claim 3 (depends on 1)

The method of claim 1, wherein the therapeutic peptide or multivalent structured polypeptide functionally mimics a glycan with a terminal N-actetylgalactosamine or galactose residue to activate the lectin-type receptor.

### Claim 4 (depends on 1)

The method of claim 1, wherein activation of the lectin-type receptor induces phosphorylation of p53, CREB, and/or PRAS40 in the cytoplasm of the cell.

### Claim 5 (depends on 1)

The method of claim 1, wherein the multivalent structured polypeptide is branched.

### Claim 6 (depends on 5)

The method of claim 5, wherein the multivalent structured polypeptide is a quadravalent structure.

### Claim 7 (depends on 1)

The method of claim 1, wherein the therapeutic peptide consists of N-Q-H-T-P-R-X7-X8 (SEQ ID NO: 13), and wherein X7 is S, L, or is absent, and X8 is G, or is absent.

### Claim 8 (depends on 7)

The method of claim 7, wherein the therapeutic peptide consists of NQHTPR (SEQ ID NO:5).

### Claim 9 (depends on 8)

The method of claim 8, wherein the multivalent structured polypeptide is branched.

### Claim 10 (depends on 9)

The method of claim 9, wherein the multivalent structured polypeptide is a quadravalent structure.

### Claim 11 (depends on 1)

The method of claim 1, wherein the cell is an immune cell.

### Claim 12 (depends on 11)

The method of claim 11, wherein the immune cell is selected from the group consisting of a macrophage; dendritic cell; natural killer cell; natural killer T cell; CD3+, CD4+ and CD8+ T cell; and B cell.

### Claim 13

A therapeutic composition, comprising:
a multivalent structured polypeptide comprising multiple copies of a therapeutic peptide in an amount sufficient to activate a lectin-type receptor specific for N-actetylgalactosamine or galactose in vivo, wherein the therapeutic peptide comprises NQHTPR (SEQ ID NO:5) and the multivalent structured polypeptide is a branched, quadravalent structure; and
at least one agent selected from the group consisting of: a B cell proliferative agent, a cytotoxic T cell proliferation agent, and an NK cell proliferation agent.

### Claim 14 (depends on 13)

The therapeutic composition of claim 13, wherein the lectin-type receptor is CLEC10a, langerin, ASGPR-1 or dectin-1.

### Claim 15 (depends on 13)

The therapeutic composition of claim 13, wherein the therapeutic peptide consists of N-Q-H-T-P-R-X7-X8 (SEQ ID NO: 13), and wherein X7 is S, L, or is absent, and X8 is G, or is absent.

### Claim 16 (depends on 15)

The therapeutic composition of claim 15, wherein the therapeutic peptide consists of NQHTPR (SEQ ID NO:5).

### Claim 17 (depends on 13)

The therapeutic composition of claim 13, wherein the at least one agent consists of a B cell proliferative agent.

### Claim 18 (depends on 13)

The therapeutic composition of claim 13, wherein the at least one agent consists of a cytotoxic T cell proliferation agent.

### Claim 19 (depends on 13)

The therapeutic composition of claim 13, wherein the at least one agent consists of an NK cell proliferation agent.

### Claim 20 (depends on 13)

The therapeutic composition of claim 13, further comprising a pharmaceutically acceptable carrier.